Study Details

Additional Information

This is a research study for Denosumab, a commercially available drug marketed as Prolia® or Xgeva® and used to treat conditions of the bones, such as osteoporosis and the prevention of skeletal-related events in solid tumors. The purpose of this study is to compare the blood levels of the approved formulation to an investigational formulation.

• Healthy Non-Smoking Adults, age 18-65
  
  
• BMI (body mass index) 18-30
  
  
• Join us for a stay of 8 nights followed by 11 outpatient visits
  
  
• Compensation up to $7658 may be provided for time and participation

Details

Screening: Dec 11, 12, 13, 16, 17, 18, 19, 20, 23, 30 & 31

Check-in: Jan 07
Check-out: Jan 15

Outpatient Visit: Jan 18

Outpatient Visit: Jan 22

Outpatient Visit: Jan 29

Outpatient Visit: Feb 05

Outpatient Visit: Feb 19

Outpatient Visit: Mar 04

Outpatient Visit: Mar 18

Outpatient Visit: Apr 01

Outpatient Visit: Apr 15

Outpatient Visit: Apr 29

Outpatient Visit: May 13